Challenges and Opportunities with Checkpoint Inhibition for First-Line Management of Advanced NSCLC: A Care Team Forum℠

Program Overview

This activity was designed to improve the knowledge and competence of clinicians with respect to biomarker testing, selection of first-line checkpoint inhibitor therapy, and management of immunotherapy-related adverse events in patients with advanced NSCLC.

Credit Expired
0.75 CE Credit(s)
Expires: October 18, 2022

Target Audience

This activity is intended for medical oncology, pathology, and pulmonology clinicians who are involved in the management of patients with advanced non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Employ evidence-based biomarker testing for patients with NSCLC
  • Select first-line checkpoint inhibitor therapy based on scientific evidence and therapeutic indications for patients with NSCLC
  • Apply evidence-based strategies for the management of immunotherapy-related adverse events in patients with NSCLC

Activity Faculty


Solange Peters, MD, PhD

Chair and Professor, Medical Oncology
University Hospital of Lausanne
Lausanne, Switzerland

Kerr, Keith - Headshot

Prof. Keith M. Kerr, FRCPath

Honorary Chair, Department of Pathology
Aberdeen University School of Medicine
Aberdeen Royal Infirmary
Foresterhill, Aberdeen,
Scotland, United Kingdom

Ramalingam - Headshot

Suresh S. Ramalingam, MD, FACP, FASCO

Professor, Hematology and Medical Oncology
Roberto C. Goizueta Chair, Cancer Research
Director, Division of Medical Oncology
Assistant Dean, Cancer Research
Deputy Director, Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia, United States


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources